Fiche du document
2016
- doi: 10.1186/s12885-016-2434-7
- issn: 1471-2407
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1186/s12885-016-2434-7
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/27378078
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1471-2407
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_B68AD93A86574
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Leptomeningitis CaseCiter ce document
C. Maritaz et al., « Cetuximab-induced aseptic meningitis: case report and review of a rare adverse event. », Serveur académique Lausannois, ID : 10.1186/s12885-016-2434-7
Métriques
Partage / Export
Résumé
BACKGROUND: Cetuximab is a commonly used antibody agent in the treatment of colorectal or head and neck cancer. Although it is generally well tolerated in most patients, cetuximab has been associated with some rare but serious adverse events. Aseptic meningitis is one such distinctly uncommon adverse drug reaction. CASE PRESENTATION: We present the case of a middle-aged Caucasian patient, who presented with fever and headache within a few hours of starting cetuximab therapy and was diagnosed with cetuximab-induced aseptic meningitis after a complete workup. CONCLUSION: To our knowledge, this is the ninth case of cetuximab-induced aseptic meningitis reported in literature. Because of a nonspecific clinical presentation, this adverse drug reaction can be easily misdiagnosed. It is important to increase awareness of this potentially severe reaction among oncologists.